David Boulware

Last updated
David Boulware
Boulware Head 2023.jpg
Born1974 (age 49–50)
United States
CitizenshipUnited States, United Kingdom [explain status]
Alma mater Indiana University School of Medicine
Occupation Physician infectious diseases (medical specialty)
Years active2004–present
Known for COVID-19, meningitis, HIV researcher
TitleProfessor of Medicine at University of Minnesota

David Boulware is a professor of medicine and a practicing infectious disease physician at the University of Minnesota Medical School. He is a member of the graduate faculty for the University of Minnesota School of Public Health Epidemiology PhD program and for the Microbiology, Immunology, and Cancer Biology (MICaB) graduate program. Boulware was the first Lois & Richard King Distinguished Assistant Professorship at the University of Minnesota. Boulware is an active medical researcher engaged in clinical trials in infectious diseases. [1] His expertise is particularly in the realm of HIV-related meningitis, including Cryptococcosis and Tuberculous meningitis.

Contents

Education

Boulware graduated from Wabash College in 1996 with a Bachelor of Arts in Chemistry. [2] He later attended the Indiana University School of Medicine, graduating in 2000. [3] He completed various residencies and fellowships from 2000-2007, receiving a certificate in tropical medicine from the Centers for Disease Control and Prevention (CDC) in 2006. He completed his master's in public health in 2007.

Career

Boulware joined the faculty of the University of Minnesota in 2007, becoming an Assistant Professor of Medicine in the Division of Infectious Disease and International Medicine at the University of Minnesota’s Department of Medicine. Around the same time, he began working within the university’s Center for Infectious Diseases and Microbiology Translational Research (CIDMTR) to study HIV/AIDS and cryptococcal meningitis with the Infectious Diseases Institute in Uganda. [4]

He was named to the Lois and Richard King Distinguished Assistant Professorship at the school in 2011. [2]

COVID-19

Boulware's primary research has been focused on improving the diagnosis, prevention, and treatment of cryptococcal meningitis. [5] However, he is best known for outpatient COVID-19 clinical trials, pioneering remote de-centralized, internet-based clinical trials during the COVID-19 pandemic.

Boulware's team rapidly launched a series of three U.S. nationwide randomized clinical trials testing hydroxychloroquine for post-exposure prophylaxis, early treatment, and pre-exposure prophylaxis for prevention of COVID-19 on March 17, 2020. [6] These were among the first U.S. trials to be launched. [7] The pre-exposure prophylaxis trial was reported June 3, 2020 showing that taking hydroxychloroquine was not effective at preventing COVID-19. [8] [9] [10] As described, "To say that the recruitment of this post-exposure prophylaxis trial was innovative hardly gives the methods enough credit." [11] These trials were pioneering for being remote internet-based randomized decentralized clinical trials. [12] [13]

The hydroxychloroquine early treatment trial was the first large phase III, outpatient randomized clinical trial testing an outpatient therapy for COVID-19. [14] [15] Subsequent, meta-analysis of 11 outpatient hydroxychloroquine randomized trials of 2037 participants showed zero benefit for reducing hospitalization [16] While pre-exposure prophylaxis with hydroxychloroquine for prevention was promoted on May 18, 2020, [17] the subsequent randomized trial did not show any benefit. [18]

Describing the experimental antiviral drug remdesivir in June 2020, Boulware said that the medicine could provide "a reasonable value" if it reduced the length of stay in hospital for COVID-19 patients. [19] This true early in the pandemic waves when hospital beds were in limited supply.

Boulware served as senior investigator on other trials testing early treatments for COVID-19 including the TogetherTrial ivermectin;, [20] [21] which demonstrated that ivermectin did not have a clinical benefit for early COVID-19. [22] University of Minnesota's COVID-Out randomized trial testing metformin, ivermectin, and fluvoxamine. [23] The Covid-Out trial reported a 42% reduction in COVID-related emergency room visits and hospitalizations through 14-days with the use of metformin. [24] Metformin also had a 58% reduction in hospitalizations through 28-days and reduced long COVID by 41% through 10-months. In December 2021 at the beginning of the Omicron wave, Boulware took the initiative to apply to the U.S. FDA for an Emergency Use Authorization for fluvoxamine 100 mg twice daily. [25] This low cost generic medicine of fluvoxamine reduced covid-related hospitalizations by 25% as well as reducing ER visits and hospitalizations. [26] FDA rejected the EUA request for this low cost generic medicine questioning whether reducing prolonged ER visits and hospitalizations represents a clinically meaningful benefit. [27] Dr. Boulware has been a proponent of repurposed medicines which actually have benefit for COVID-19, including metformin, interferon-lambda, and higher-dose fluvoxamine. [28]

Boulware serves as the national co-chair of the trial steering committee for the NIH ACTIV-6 platform clinical trial testing repurposed medicines for COVID-19. [29] [30] ACTIV-6 trial has tested outpatient COVID-19 therapies including ivermectin, inhaled fluticasone, low-dose fluvoxamine 50mg twice daily, fluvoxamine 100mg twice daily, montelukast, and metformin.

Notable contributions and honors

Related Research Articles

<i>Cryptococcus neoformans</i> Species of yeast

Cryptococcus neoformans is an encapsulated yeast belonging to the class Tremellomycetes and an obligate aerobe that can live in both plants and animals. Its teleomorph is a filamentous fungus, formerly referred to Filobasidiella neoformans. In its yeast state, it is often found in bird excrement. Cryptococcus neoformans can cause disease in apparently immunocompetent, as well as immunocompromised, hosts.

<span class="mw-page-title-main">Cryptococcosis</span> Potentially fatal fungal disease

Cryptococcosis is a potentially fatal fungal infection of mainly the lungs, presenting as a pneumonia, and brain, where it appears as a meningitis. Cough, difficulty breathing, chest pain and fever are seen when the lungs are infected. When the brain is infected, symptoms include headache, fever, neck pain, nausea and vomiting, light sensitivity and confusion or changes in behavior. It can also affect other parts of the body including skin, where it may appear as several fluid-filled nodules with dead tissue.

Post-exposure prophylaxis, also known as post-exposure prevention (PEP), is any preventive medical treatment started after exposure to a pathogen in order to prevent the infection from occurring.

<span class="mw-page-title-main">Ivermectin</span> Medication for parasite infestations

Ivermectin is an antiparasitic drug. After its discovery in 1975, its first uses were in veterinary medicine to prevent and treat heartworm and acariasis. Approved for human use in 1987, it is used to treat infestations including head lice, scabies, river blindness (onchocerciasis), strongyloidiasis, trichuriasis, ascariasis and lymphatic filariasis. It works through many mechanisms to kill the targeted parasites, and can be taken by mouth, or applied to the skin for external infestations. It belongs to the avermectin family of medications.

<span class="mw-page-title-main">Chloroquine</span> Medication used to treat malaria

Chloroquine is a medication primarily used to prevent and treat malaria in areas where malaria remains sensitive to its effects. Certain types of malaria, resistant strains, and complicated cases typically require different or additional medication. Chloroquine is also occasionally used for amebiasis that is occurring outside the intestines, rheumatoid arthritis, and lupus erythematosus. While it has not been formally studied in pregnancy, it appears safe. It was studied to treat COVID-19 early in the pandemic, but these studies were largely halted in the summer of 2020, and the NIH does not recommend its use for this purpose. It is taken by mouth.

<span class="mw-page-title-main">Hydroxychloroquine</span> Antimalarial medication

Hydroxychloroquine, sold under the brand name Plaquenil among others, is a medication used to prevent and treat malaria in areas where malaria remains sensitive to chloroquine. Other uses include treatment of rheumatoid arthritis, lupus, and porphyria cutanea tarda. It is taken by mouth, often in the form of hydroxychloroquine sulfate.

Moses R Kamya, is a Ugandan physician, academic, researcher and academic administrator, who serves as Professor and Chair of the Department Medicine, Makerere University School of Medicine, a component of Makerere University College of Health Sciences.

<span class="mw-page-title-main">Oriol Mitjà</span> Catalan researcher

Oriol Mitjà i Villar is a Catalan-born Spanish researcher and consultant physician in internal medicine and infectious diseases with expertise in poverty-related tropical diseases. He has conducted research at the Lihir Medical Centre in Papua New Guinea since 2010 on new diagnostic and therapeutic tools to eradicate yaws. He was awarded the Princess of Girona Award in the scientific research category. Currently at the Germans Trias i Pujol Research Institute, Mitjà is conducting research on SARS-CoV-2 coronavirus disease (COVID-19) and strategies to control the infection at a community level.

<span class="mw-page-title-main">COVID-19 drug repurposing research</span> Drug repurposing research related to COVID-19

Drug repositioning is the repurposing of an approved drug for the treatment of a different disease or medical condition than that for which it was originally developed. This is one line of scientific research which is being pursued to develop safe and effective COVID-19 treatments. Other research directions include the development of a COVID-19 vaccine and convalescent plasma transfusion.

<span class="mw-page-title-main">COVID-19 drug development</span> Preventative and therapeutic medications for COVID-19 infection

COVID-19 drug development is the research process to develop preventative therapeutic prescription drugs that would alleviate the severity of coronavirus disease 2019 (COVID-19). From early 2020 through 2021, several hundred drug companies, biotechnology firms, university research groups, and health organizations were developing therapeutic candidates for COVID-19 disease in various stages of preclinical or clinical research, with 419 potential COVID-19 drugs in clinical trials, as of April 2021.

<span class="mw-page-title-main">Solidarity trial</span> Accelerated multinational clinical trial program to identify therapies against COVID-19

The Solidarity trial for treatments is a multinational Phase III-IV clinical trial organized by the World Health Organization (WHO) and partners to compare four untested treatments for hospitalized people with severe COVID-19 illness. The trial was announced 18 March 2020, and as of 6 August 2021, 12,000 patients in 30 countries had been recruited to participate in the trial.

<span class="mw-page-title-main">Annie Luetkemeyer</span> American physician and infectious diseases researcher

Annie F. Luetkemeyer is an American physician and researcher who is Professor of Medicine and Infectious Diseases at the University of California, San Francisco. She specializes in infectious diseases, in particular tuberculosis, human immunodeficiency virus and viral hepatitis. During the COVID-19 pandemic Luetkemeyer led a clinical trial of remdesivir. She has also researched treatment of COVID-19 as a co-infection with HIV.

<span class="mw-page-title-main">Jeanne Marrazzo</span> American microbiologist

Jeanne Marisa Marrazzo is an American physician-scientist and infectious diseases specialist. She was the director of the University of Alabama School of Medicine Division of Infectious Diseases and focused on prevention of HIV infection using biomedical interventions. Marrazzo is a fellow of the American College of Physicians and Infectious Disease Society of America. On August 2, 2023 Lawrence A. Tabak, acting director for the National Institutes of Health (NIH), named Jeanne M. Marrazzo as director of NIH’s National Institute of Allergy and Infectious Diseases.

The treatment and management of COVID-19 combines both supportive care, which includes treatment to relieve symptoms, fluid therapy, oxygen support as needed, and a growing list of approved medications. Highly effective vaccines have reduced mortality related to SARS-CoV-2; however, for those awaiting vaccination, as well as for the estimated millions of immunocompromised persons who are unlikely to respond robustly to vaccination, treatment remains important. Some people may experience persistent symptoms or disability after recovery from the infection, known as long COVID, but there is still limited information on the best management and rehabilitation for this condition.

<span class="mw-page-title-main">RECOVERY Trial</span> Test of existing medicines on COVID-19

The Randomised Evaluation of COVID-19 Therapy is a large-enrollment clinical trial of possible treatments for people in the United Kingdom admitted to hospital with severe COVID-19 infection. The trial was later expanded to Indonesia, Nepal and Vietnam. The trial has tested ten interventions on adults: eight repurposed drugs, one newly developed drug and convalescent plasma.

Andrew Ddungu Kambugu is a Ugandan physician who serves as The Sande-McKinnell Executive Director at Uganda Infectious Disease Institute and a Honorary Senior lecturer at Makerere University College of Sciences. He is also an Adjunct Associate Professor at the University of Minnesota. In July 2020, he was appointed to the United Nations 2021 Food System Scientific Group.

<span class="mw-page-title-main">Pierre Kory</span> American physician

Pierre Kory is an American critical care physician who gained attention during the COVID-19 pandemic for advocating widespread off-label use of certain drugs as treatments for COVID-19, as president and co-founder of the Front Line COVID-19 Critical Care Alliance (FLCCC). Kory testified twice to the U.S. Senate regarding COVID-19. During his testimony in December 2020, Kory erroneously claimed that the antiparasitic medication ivermectin was a "wonder drug" with "miraculous effectiveness" against COVID-19.

<span class="mw-page-title-main">Chloroquine and hydroxychloroquine during the COVID-19 pandemic</span> Early experimental treatment efforts during the start of COVID-19 pandemic

Chloroquine and hydroxychloroquine are anti-malarial medications also used against some auto-immune diseases. Chloroquine, along with hydroxychloroquine, was an early experimental treatment for COVID-19. Neither drug has been useful to prevent or treat SARS-CoV-2 infection. Administration of chloroquine or hydroxychloroquine to COVID-19 patients has been associated with increased mortality and adverse effects, such as QT prolongation. Researchers estimate that off-label use of hydroxychloroquine in hospitals during the first phase of the pandemic caused 17,000 deaths worldwide. The widespread administration of chloroquine or hydroxychloroquine, either as monotherapies or in conjunction with azithromycin, has been associated with deleterious outcomes, including QT interval prolongation. As of 2024, scientific evidence does not substantiate the efficacy of hydroxychloroquine, with or without the addition of azithromycin, in the therapeutic management of COVID-19.

Onyema Eberechukwu Ogbuagu is an American-born infectious diseases physician, educator, researcher, and clinical trial investigator, who was raised and educated in Nigeria. He is an associate professor at Yale School of Medicine in New Haven, CT and is the director of the Yale AIDS Program clinical trials unit. His research contributions have focused on HIV/AIDS prevention and COVID-19 vaccination and treatment clinical trials. He switched his focus at the beginning of the 2019 COVID pandemic and participated as a principal investigator (PI) on the Pfizer-BioNtech COVID-19 vaccine trials and the Remdesivir SIMPLE trial in 2020 and 2021. In pursuit of his global health component of his career, Ogbuagu also supports postgraduate physician medical education programs in low and middle income countries in sub-Saharan Africa in Rwanda (2013–2018) and Liberia as well as HIV treatment programs in Liberia.

<span class="mw-page-title-main">Ivermectin during the COVID-19 pandemic</span> Uses of drug ivermectin during the COVID-19 pandemic

Ivermectin is an antiparasitic drug that is well established for use in animals and people. The World Health Organization (WHO), the European Medicines Agency (EMA), the United States Food and Drug Administration (FDA), and the Infectious Diseases Society of America (IDSA) all advise against using ivermectin in an attempt to treat or prevent COVID-19.

References

  1. ↑ "David R Boulware". University of Minnesota . Archived from the original on 2023-05-18. Retrieved 2023-05-21.
  2. 1 2 "Dr. David Boulware '96/King Distinguished Professor at UMN – Alumni News". Wabash College . 2011-11-04. Archived from the original on 2023-05-17. Retrieved 2023-05-17.
  3. ↑ Boulware, David R. (2021-04-29). "Clinical & Translational Research in Cryptococcosis" (PDF). Mycoses Study Group Education & Research Consortium. Archived (PDF) from the original on 2023-05-17. Retrieved 2023-05-17.
  4. ↑ Schmickle, Sharon (2008-11-13). "University of Minnesota doctors battle AIDS in Uganda". MinnPost . Archived from the original on 2010-06-23. Retrieved 2023-05-21.
  5. ↑ Adams, Patrick (4 January 2016). "Crushing Crypto, the deadly, neglected disease that kills 300K every year". Newsweek.
  6. ↑ Boulware, David R.; Pullen, Matthew F.; Bangdiwala, Ananta S.; Pastick, Katelyn A.; Lofgren, Sarah M.; Okafor, Elizabeth C.; Skipper, Caleb P.; Nascene, Alanna A.; Nicol, Melanie R.; Abassi, Mahsa; Engen, Nicole W.; Cheng, Matthew P.; LaBar, Derek; Lother, Sylvain A.; MacKenzie, Lauren J.; Drobot, Glen; Marten, Nicole; Zarychanski, Ryan; Kelly, Lauren E.; Schwartz, Ilan S.; McDonald, Emily G.; Rajasingham, Radha; Lee, Todd C.; Hullsiek, Kathy H. (6 August 2020). "A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for COVID-19". New England Journal of Medicine. 383 (6): 517–525. doi:10.1056/NEJMoa2016638. PMC   7289276 . PMID   32492293.
  7. ↑ Palca, Joe (31 March 2020). "Clinical Trials Set To Determine If Anti-Malaria Drug Effective Against COVID-19". NPR.
  8. ↑ Grady, Denise (3 June 2020). "Malaria Drug Promoted by Trump Did Not Prevent COVID Infections, Study Finds". The New York Times.
  9. ↑ "Hydroxychloroquine, a drug promoted by Trump, failed to prevent healthy people from getting covid-19 in trial". Washington Post.
  10. ↑ "White House asked for Dr. Boulware's advice on hydroxychloroquine. This is what he said - CNN Video". CNN.
  11. ↑ Sax, Paul (7 June 2020). "Hydroxychloroquine Not Effective in Preventing COVID-19 -- In Praise of a Negative Clinical Trial". HIV and ID Observations. NEJM Journal Watch.
  12. ↑ Adam, Rogers. "The Strange and Twisted Tale of Hydroxychloroquine". Wired.
  13. ↑ "How to Conduct a Clinical Trial During a Pandemic—An Interview with Dr. David Boulware". Open Forum Infectious Diseases. 7 (7): ofaa277. 1 July 2020. doi: 10.1093/ofid/ofaa277 . PMC   7534549 . PMID   33043070.
  14. ↑ "Hydroxychloroquine studies show drug is not effective for early treatment of mild covid-19". Washington Post.
  15. ↑ Skipper, Caleb P.; Pastick, Katelyn A.; Engen, Nicole W.; Bangdiwala, Ananta S.; Abassi, Mahsa; Lofgren, Sarah M.; Williams, Darlisha A.; Okafor, Elizabeth C.; Pullen, Matthew F.; Nicol, Melanie R.; Nascene, Alanna A.; Hullsiek, Kathy H.; Cheng, Matthew P.; Luke, Darlette; Lother, Sylvain A.; MacKenzie, Lauren J.; Drobot, Glen; Kelly, Lauren E.; Schwartz, Ilan S.; Zarychanski, Ryan; McDonald, Emily G.; Lee, Todd C.; Rajasingham, Radha; Boulware, David R. (20 October 2020). "Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial". Annals of Internal Medicine. 173 (8): 623–631. doi:10.7326/M20-4207. PMC   7384270 . PMID   32673060.
  16. ↑ Mitjà, Oriol; Reis, Gilmar; Boulware, David R.; Spivak, Adam M.; Sarwar, Ammar; Johnston, Christine; Webb, Brandon; Hill, Michael D.; Smith, Davey; Kremsner, Peter; Curran, Marla; Carter, David; Alexander, Jim; Corbacho, Marc; Lee, Todd C.; Hullsiek, Katherine Huppler; McDonald, Emily G.; Hess, Rachel; Hughes, Michael; Baeten, Jared M.; Schwartz, Ilan; Metz, Luanne; Richer, Lawrence; Chew, Kara W.; Daar, Eric; Wohl, David; Dunne, Michael (March 2023). "Hydroxychloroquine for treatment of non-hospitalized adults with COVID -19: A meta-analysis of individual participant data of randomized trials". Clinical and Translational Science. 16 (3): 524–535. doi: 10.1111/cts.13468 . PMC   10014689 . PMID   36601684.
  17. ↑ McDonald, Jessica; Rieder, Rem (21 May 2020). "Trump Misleads on Hydroxychloroquine, Again". FactCheck.org.
  18. ↑ Rajasingham, Radha; Bangdiwala, Ananta S; Nicol, Melanie R; Skipper, Caleb P; Pastick, Katelyn A; Axelrod, Margaret L; Pullen, Matthew F; Nascene, Alanna A; Williams, Darlisha A; Engen, Nicole W; Okafor, Elizabeth C; Rini, Brian I; Mayer, Ingrid A; McDonald, Emily G; Lee, Todd C; Li, Peter; MacKenzie, Lauren J; Balko, Justin M; Dunlop, Stephen J; Hullsiek, Katherine H; Boulware, David R; Lofgren, Sarah M; Abassi, Mahsa; Balster, Andrew; Collins, Lindsey B; Drobot, Glen; Krakower, Douglas S; Lother, Sylvain A; MacKay, Dylan S; Meyer-Mueller, Cameron; Selinsky, Stephen; Solvason, Dayna; Zarychanski, Ryan; Zash, Rebecca (1 June 2021). "Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial". Clinical Infectious Diseases. 72 (11): e835–e843. doi:10.1093/cid/ciaa1571. PMC   7665393 . PMID   33068425.
  19. ↑ "Drug company to charge thousands for coronavirus treatment". NBC News . Associated Press. 2020-06-29. Archived from the original on 2022-11-08. Retrieved 2023-05-18.
  20. ↑ "TOGETHER Trial". TOGETHER Trial.
  21. ↑ Reis, Gilmar; Silva, Eduardo A.S.M.; Silva, Daniela C.M.; Thabane, Lehana; Milagres, Aline C.; Ferreira, Thiago S.; dos Santos, Castilho V.Q.; Campos, Vitoria H.S.; Nogueira, Ana M.R.; de Almeida, Ana P.F.G.; Callegari, Eduardo D.; Neto, Adhemar D.F.; Savassi, Leonardo C.M.; Simplicio, Maria I.C.; Ribeiro, Luciene B.; Oliveira, Rosemary; Harari, Ofir; Forrest, Jamie I.; Ruton, Hinda; Sprague, Sheila; McKay, Paula; Guo, Christina M.; Rowland-Yeo, Karen; Guyatt, Gordon H.; Boulware, David R.; Rayner, Craig R.; Mills, Edward J. (5 May 2022). "Effect of Early Treatment with Ivermectin among Patients with COVID-19". New England Journal of Medicine. 386 (18): 1721–1731. doi:10.1056/NEJMoa2115869. PMC   9006771 . PMID   35353979.
  22. ↑ Zimmer, Carl (30 March 2022). "Ivermectin Does Not Reduce Risk of COVID Hospitalization, Large Study Finds". The New York Times.
  23. ↑ "COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)". ClinicalTrials.gov. 2 March 2022.
  24. ↑ Bramante, Carolyn T.; Huling, Jared D.; Tignanelli, Christopher J.; Buse, John B.; Liebovitz, David M.; Nicklas, Jacinda M.; Cohen, Kenneth; Puskarich, Michael A.; Belani, Hrishikesh K.; Proper, Jennifer L.; Siegel, Lianne K.; Klatt, Nichole R.; Odde, David J.; Luke, Darlette G.; Anderson, Blake; Karger, Amy B.; Ingraham, Nicholas E.; Hartman, Katrina M.; Rao, Via; Hagen, Aubrey A.; Patel, Barkha; Fenno, Sarah L.; Avula, Nandini; Reddy, Neha V.; Erickson, Spencer M.; Lindberg, Sarah; Fricton, Regina; Lee, Samuel; Zaman, Adnin; Saveraid, Hanna G.; Tordsen, Walker J.; Pullen, Matthew F.; Biros, Michelle; Sherwood, Nancy E.; Thompson, Jennifer L.; Boulware, David R.; Murray, Thomas A. (18 August 2022). "Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19". New England Journal of Medicine. 387 (7): 599–610. doi: 10.1056/NEJMoa2201662 . PMC   9945922 . PMID   36070710. S2CID   251659997.
  25. ↑ "Doctor Submits Fluvoxamine EUA Application to FDA". www.medpagetoday.com. 29 December 2021.
  26. ↑ Lee, Todd C.; Vigod, Simone; Bortolussi-Courval, Émilie; Hanula, Ryan; Boulware, David R.; Lenze, Eric J.; Reiersen, Angela M.; McDonald, Emily G. (6 April 2022). "Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis". JAMA Network Open. 5 (4): e226269. doi: 10.1001/jamanetworkopen.2022.6269 . PMC   8987902 . PMID   35385087.
  27. ↑ "Memorandum Explaining Basis for Declining Request for Emergency Use Authorization of Fluvoxamine Maleate" (PDF). FDA. Retrieved 5 March 2022.
  28. ↑ "Three effective treatments for COVID-19 not (yet) in guidelines". IDSA Podcast. Retrieved 23 March 2023.
  29. ↑ "Activ-6 Study".
  30. ↑ "ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications". clinicaltrials.gov. 22 March 2022.
  31. ↑ "Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy". www.who.int. World Health Organization.
  32. ↑ "Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children". www.who.int. World Health Organization.
  33. ↑ "US HHS/NIH/CDC HIV Opportunistic Infection Guidelines | NIH". clinicalinfo.hiv.gov. US HHS. 29 July 2024.
  34. ↑ "David R. Boulware, MD, MPH". The American Society for Clinical Investigation.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.